How much does a box of Pralsetinib cost?

Pralsetinib (Pralsetinib) is a potent and selective RET receptor tyrosine kinase inhibitor. The main purpose of the ARROW trial is to evaluate the efficacy and safety of platinib in patients with advanced RET-altered solid tumors. The study shows that platinib is a well-tolerated treatment option with rapid, powerful and durable anti-tumor activity in patients with RET fusion-positive solid tumors, including non-small cell lung cancer and thyroid cancer.

Platinib is suitable for patients who have previously received platinum-based chemotherapy. Patients who have not received treatment have not reached the median duration of response, and patients who have previously received platinum-based chemotherapy have not reached the median duration of response 22.3 months. Tumor shrinkage was observed in all treatment-naive patients and in 97% of patients who had previously received platinum-based chemotherapy; median progression-free survival was 13.0 and 16.5 months, respectively. In treatment-naive patients with RET fusion-positive NSCLC who were initiated on platinib at the time of data cutoff, the most common grade 3-4 treatment-related adverse events were neutropenia, hypertension, elevated blood creatine phosphokinase, and lymphopenia.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.